Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma-Reference-Cited by-同舟云学术

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

Published:2007-10-01 Issue:3 Volume:139 Page:425-428
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

O'Connor Owen A.,Hamlin Paul A.,Portlock Carol,Moskowitz Craig H.,Noy Ariela,Straus David J.,MacGregor-Cortelli Barbara,Neylon Ellen,Sarasohn Debra,Dumetrescu Otila,Mould Diane R.,Fleischer Martin,Zelenetz Andrew D.,Sirotnak Frank,Horwitz Steven

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06658.x/fullpdf

Reference12 articles.

1. Non-Hodgkin's lymphoma time trends: United States and international data;Devesa;Cancer Research,1992

2. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA);Gisselbrecht;Blood,1998

3. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate;Krug;Clinical Cancer Research,2000

4. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer;Krug;Clinical Cancer Ressearch,2003

5. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2005

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas;Haematologica;2023-11-21

2. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients;Journal of the Formosan Medical Association;2023-08

3. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind;Anti-Cancer Agents in Medicinal Chemistry;2023-02

4. Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2022-10-20

5. Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas;Journal of Personalized Medicine;2022-02-11